Kosel Medical Completes Over RMB 100 Million Series B Financing to Advance Platform Strategy in Vascular Intervention

VCBeat learned第一时间 that recently, Kossel Medtech (Suzhou) Co., Ltd. has completed a B-round financing of over 100 million yuan.This round of financing was led byFortune CapitalLead investment,Suzhou Intenational Development Veture Capital Holding、Suzhou New DISTRICT HI-TECH Industrial Co., Ltd.AndMedparkFollow-up Investment.

Kossel Founder and CEO Hu QingKossel: 2024 Marks the Beginning of Kossel's Third Five-Year Plan. The successful completion of this round of financing fully demonstrates investors' continued confidence in Kossel Medtech, as well as their strong belief in the company’s product positioning, competitiveness, and future prospects. This round of financing will help the company deepen its platform-based and international vascular intervention strategies, expand its product pipeline, enlarge production bases, and attract more top-tier talent to support the goal of becoming "a leading innovative medical device enterprise in China’s vascular intervention field with global recognition." Kossel staff will continue to align knowledge with action, work pragmatically, stay attuned to industry trends, foster win-win cooperation with all parties, and jointly build a robust industry ecosystem.

Kossel is a national high-tech enterprise and a national specialized, refined, novel "little giant" enterprise. It undertakes major scientific and technological achievement transformation projects in Jiangsu Province, and has been approved as a provincial and municipal engineering technology research center and enterprise technology center. It has successively been recognized as a potential unicorn enterprise in Jiangsu Province, a gazelle enterprise in the high-tech zone of Jiangsu Province, a unicorn cultivation enterprise in Suzhou City, and a potential landmark enterprise in the biopharmaceutical industry in Suzhou City.

After ten years of hard work, Kossel has completed its platform-based layout: the parent company, Kossel, focuses on building a "one-stop" treatment system in the peripheral intervention field; its subsidiary, Haiyu Xincheng, provides comprehensive solutions for the treatment of rapid arrhythmia; its subsidiary, Mixin Medical, concentrates on the development of products in the coronary intervention field and the transformation of overseas products and technologies; its subsidiary, Haiwang Medical, is committed to the research and development of core raw materials that address critical bottlenecks. Kossel Medical actively promotes the "Going Out" strategy and took a solid step towards globalization by acquiring Micell at the end of 2021.

Kossel Medtech always adheres to the concept of "originating from clinical practice and serving clinical practice," practices the combination of medical and engineering, continuously invests in research, development, and lean manufacturing, holds more than 200 invention patents, over 70 PCT patents, and more than 20 Class III medical device registration certificates in China and abroad. With global registration and active expansion overseas, Kossel Medtech has become a well-known enterprise in the field of vascular interventional medical devices.

Fortune CapitalKossel Medtech is a company with unique competitiveness. In addition to the essential qualifications and potential of the invested enterprises, the strategic vision of Kossel Medtech's founder, platformization and globalization layout, pragmatic corporate culture, cohesive core team, continuous R&D investment, and strong R&D capabilities are important considerations for our investment decision. We believe that Kossel Medtech will surely achieve long-term stable development.

Suzhou Intenational Development Veture Capital HoldingKossel Medtech's pragmatic and efficient team, clear and robust business model, and the enormous clinical demand for its products are the values that Suzhou Intenational Development Veture Capital Holding (referred to as "Suzhou Guofa Ventures") values. As a platform enterprise, Kossel has comprehensively laid out in the fields of peripheral intervention, cardiac electrophysiology, coronary intervention, and interventional device materials, establishing a rich product pipeline and has already made rapid commercial progress in the peripheral field. It is hoped that through this round of investment cooperation, Kossel Medtech will be supported to develop into a leading innovative enterprise in China with global competitiveness.

Suzhou New DISTRICT HI-TECH Industrial Co., Ltd. and MedparkKossel Medtech, founded and grown within Medpark, has developed into one of the medical device companies with the largest number of employees in the High-Tech Zone. It is a company with a strong sense of social responsibility. We have witnessed Kossel Medtech's ten years of growth, and we continue to be optimistic about the company’s future development. We will also provide comprehensive support as always.